Figure 3.
Antiproliferative, pro-differentiating and transactivating potency of 1,25(OH)2D3 and CY10012. (A) [3H]-Thymidine incorporation assay in human breast cancer MCF-7 cells which were treated with different doses of 1,25(OH)2D3 and analog CY10012. Means of five samples±SEM of a representative experiment are shown. (B) Induction of HL-60 differentiation by different doses of 1,25(OH)2D3 and CY10012, determined by the NBT reduction assay. Data shown are means of quadruplicates±SEM from a representative experiment. (C) Transactivating potency of 1,25(OH)2D3 and analog CY10012. Co-transfected COS-7 cells were exposed for 24 h to different concentrations of 1,25(OH)2D3 and CY10012, and the medium was assayed for the expression of human growth hormone. Data are the mean±SEM of triplicate wells from a representative experiment.